The Operating Problem

Where Regulated Execution Slows Down

Fragmented life sciences operations across manufacturing, quality, and regulatory systems

  • Disconnected batch and quality systems

    Manufacturing execution, laboratory, and ERP systems operate in isolation. Batch record review, quality checks, and release approvals require manual coordination, slowing cycle times and creating compliance gaps.

  • Slow deviation and CAPA resolution

    Deviation events, investigations, and corrective actions are tracked across disconnected systems. Root cause analysis and closure are delayed, extending batch holds and increasing regulatory exposure.

  • Fragmented pharmacovigilance workflows

    Safety data from clinical, post-market, and partner sources is collected and reviewed across separate systems. Case processing and regulatory reporting timelines are at risk when coordination fails.

  • Identity and access governance gaps

    Access to validated systems and regulated data lacks continuous enforcement. Unresolved access conflicts and manual review cycles create audit findings and expose organisations to 21 CFR Part 11 and EU GMP Annex 11 non-compliance.

  • Uncoordinated product launch and regulatory readiness

    Regulatory approvals, supply readiness, and commercial preparation are managed across separate teams and systems. Misalignment delays launches and creates last-minute compliance escalations.